Drugs / Forteplase
Forteplase
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05135546 | Dec 2021 → Feb 2023 | COVID-19 | Supergene, LLC | Terminated | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05372718 | Dec 2022 → Sep 2026 | limb ischemia | Supergene, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04688320 | Dec 2020 → Jul 2023 | pulmonary embolism | Supergene, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02301910 | May 2014 → Dec 2016 | myocardial infarction | Supergene, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Forteplase | “Fortelyzin® (the active substance Forteplase) is a recombinant non-immunogenic staphylokinase with high fibrinselective thrombolytic activity.” NCT05372718 ↗3“Fortelyzin® (the active substance Forteplase) is a recombinant non-immunogenic staphylokinase with high fibrinselective thrombolytic activity.” NCT05135546 ↗ “The active substance of Fortelyzin is Forteplase. It's recombinant protein which contains aminoacid sequence of staphylokinase.” NCT02301910 ↗ “Recombinant protein which contains aminoacid sequence of staphylokinase - Fortelizin® (the active substance is Forteplase).” NCT04688320 ↗ |
| Known as | Fortelizin | “Recombinant protein which contains aminoacid sequence of staphylokinase - Fortelizin® (the active substance is Forteplase).” NCT04688320 ↗ |
| Known as | Fortelyzin | “Fortelyzin® (the active substance Forteplase) is a recombinant non-immunogenic staphylokinase with high fibrinselective thrombolytic activity.” NCT05135546 ↗ |
| Action | Activate | “This complex activates plasminogen trapped in the thrombus.” NCT04688320 ↗ |
| Modality | Protein / enzyme biologic | “It's recombinant protein which contains aminoacid sequence of staphylokinase.” NCT02301910 ↗ |
| Route | Intravenous | “single-bolus intravenous injection of recombinant nonimmunogenic staphylokinase (Fortelyzin)” NCT02301910 ↗ |